Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

MRKR

Marker Therapeutics Inc

Apr 23 • 04:00PM ET

4.43

Dollar change +0.24
Percentage change 5.61	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DFAS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.93	Insider Own	27.80%	Shs Outstand	8.90M	Perf Week	0.57%
Market Cap	39.38M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	6.43M	Perf Month	-9.88%
Income	-16.97M	PEG	-	EPS next Q	-	Inst Own	10.46%	Short Float	1.68%	Perf Quarter	1.49%
Sales	6.81M	P/S	5.78	EPS this Y	-	Inst Trans	-44.93%	Short Ratio	5.70	Perf Half Y	45.56%
Book/sh	1.58	P/B	2.80	EPS next Y	-	ROA	-57.38%	Short Interest	0.11M	Perf Year	356.19%
Cash/sh	1.70	P/C	2.61	EPS next 5Y	-	ROE	-87.89%	52W Range	0.76 - 9.68	Perf YTD	-19.55%
Dividend Est.	-	P/FCF	-	EPS past 5Y	52.24%	ROI	-120.75%	52W High	-54.29%	Beta	1.52
Dividend TTM	-	Quick Ratio	5.57	Sales past 5Y	93.13%	Gross Margin	70.13%	52W Low	482.24%	ATR (14)	0.31
Dividend Ex-Date	-	Current Ratio	5.57	EPS Y/Y TTM	46.20%	Oper. Margin	-211.77%	RSI (14)	50.79	Volatility	7.58% 7.79%
Employees	8	Debt/Eq	0.00	Sales Y/Y TTM	-24.43%	Profit Margin	-249.13%	Recom	1.00	Target Price	40.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	32.93%	Payout	-	Rel Volume	0.63	Prev Close	4.19
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-68.07%	Earnings	Nov 09 AMC	Avg Volume	18.92K	Price	4.43
SMA20	-1.23%	SMA50	3.80%	SMA200	-0.79%	Trades		Volume	11,907	Change	5.61%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-25-21	Initiated	Piper Sandler	Overweight	$6
Mar-19-21	Initiated	Cantor Fitzgerald	Overweight	$6
May-12-20	Downgrade	Piper Sandler	Overweight → Neutral	$5 → $2.50
May-30-19	Initiated	ROTH Capital	Buy
Mar-01-19	Initiated	Janney	Buy
Dec-03-18	Upgrade	Piper Jaffray	Neutral → Overweight

Apr-08-24 07:00AM	Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies (GlobeNewswire)
Mar-25-24 05:45PM	Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results (GlobeNewswire)
Mar-22-24 12:30PM	Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (GlobeNewswire) +5.82%
Jan-22-24 07:30AM	Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for Neldaleucel as Nonproprietary Name for MT-601 (GlobeNewswire) +5.56%
Jan-08-24 09:31AM	Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization (Benzinga)
08:24AM	Loading…
08:24AM	Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization (GlobeNewswire)
Dec-21-23 11:00AM	Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During J.P. Morgan Week 2024 (GlobeNewswire)
Dec-11-23 07:00AM	Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse (GlobeNewswire) +46.85%
Nov-09-23 05:00PM	Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Sep-11-23 07:00AM	Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse (GlobeNewswire) +11.41%
Aug-30-23 08:00AM	Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +6.75%
Aug-25-23 12:07PM	Marker Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance (GuruFocus.com) -5.52%
Aug-17-23 09:03AM	Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies (Newsfile)
Aug-14-23 04:30PM	Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-23 07:00AM	Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program (GlobeNewswire)
07:00AM	Loading…
Jul-26-23 07:00AM	Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023 (GlobeNewswire)
Jul-22-23 08:12AM	Marker Therapeutics (NASDAQ:MRKR) hikes 26% this week, taking one-year gains to 95% (Simply Wall St.)
Jul-10-23 07:00AM	European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients (GlobeNewswire) +23.04%
Jun-26-23 07:00AM	Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration (GlobeNewswire) -6.59%
Jun-12-23 07:00AM	Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial (GlobeNewswire) +19.52%
May-31-23 06:30AM	Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells (GlobeNewswire) +33.84%
May-17-23 06:11AM	Marker Therapeutics First Quarter 2023 Earnings: US$0.57 loss per share (vs US$1.19 loss in 1Q 2022) (Simply Wall St.)
May-08-23 07:30AM	Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer (GlobeNewswire) +15.97%
May-01-23 07:30AM	Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady (GlobeNewswire) +16.47%
Mar-22-23 08:10AM	Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results (GlobeNewswire) -31.82%
Dec-13-22 07:23PM	Marker Therapeutics inks $25M stock purchase agreement with Lincoln Park Capital Fund (American City Business Journals)
07:00AM	Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million (GlobeNewswire)
Nov-22-22 07:28AM	Here's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash Wisely (Simply Wall St.)
07:00AM	Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer (GlobeNewswire)
Nov-10-22 05:35PM	MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	Marker Therapeutics Reports Q3 2022 Operating and Financial Results (GlobeNewswire)
Sep-13-22 07:00AM	Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Markers Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML (GlobeNewswire) +7.12%
Sep-08-22 07:00AM	Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference (GlobeNewswire) +31.50%
Aug-11-22 04:22PM	Marker Therapeutics Reports Q2 2022 Operating and Financial Results (GlobeNewswire) -8.08%
Aug-04-22 04:37PM	Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma (GlobeNewswire)
Jun-15-22 07:06AM	Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky (Simply Wall St.)
May-13-22 07:00AM	Marker Therapeutics Reports Q1 2022 Operating and Financial Results (GlobeNewswire)
May-04-22 10:30AM	Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting (GlobeNewswire) +8.00%
Apr-26-22 07:00AM	Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf (GlobeNewswire)
Mar-17-22 05:45PM	Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results (GlobeNewswire)
Mar-07-22 04:05PM	Marker Therapeutics to Present at Two Upcoming March Investor Conferences (GlobeNewswire)
Feb-17-22 01:08PM	Why Are Marker Therapeutics Shares Trading Lower On Thursday? (Benzinga) -25.99%
Feb-16-22 04:30PM	Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion (GlobeNewswire)
Feb-08-22 04:05PM	Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022 (GlobeNewswire)
Jan-20-22 06:38AM	Marker Therapeutics Stock Gains On FDA Orphan Drug Tag For Second MultiTAA-Cell Therapy For Pancreatic Cancer (Benzinga) -10.67%
Jan-19-22 04:49PM	Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer (GlobeNewswire)
Jan-06-22 08:53AM	Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Invest In Growth? (Simply Wall St.) -5.51%
Dec-31-21 09:40AM	Are Options Traders Betting on a Big Move in Marker Therapeutics (MRKR) Stock? (Zacks)
Dec-09-21 07:00AM	Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors (PR Newswire)
Nov-18-21 04:05PM	Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting (PR Newswire) -7.35%
Nov-10-21 04:05PM	Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results (PR Newswire)
Oct-08-21 09:24AM	Bullish insiders bet US$1.3m on Marker Therapeutics, Inc. (NASDAQ:MRKR) (Simply Wall St.)
Sep-07-21 04:05PM	Marker Therapeutics to Present at Three Upcoming September Investor Conferences (PR Newswire)
Aug-20-21 12:00PM	38 Stocks Moving In Friday's Mid-Day Session (Benzinga) +8.33%
Aug-19-21 04:05PM	Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas (PR Newswire) -5.08%
Aug-10-21 04:01PM	Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results (PR Newswire)
Aug-09-21 06:57AM	Is Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Shareholder Ownership Skewed Towards Insiders? (Simply Wall St.)
Jul-28-21 04:05PM	Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility (PR Newswire)
Jul-06-21 07:00AM	Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML (PR Newswire)
Jun-29-21 09:01AM	Marker Therapeutics, Inc. (MRKR): Are Hedge Funds Right About This Stock? (Insider Monkey)
Jun-16-21 04:05PM	Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference (PR Newswire)
May-20-21 04:06AM	Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation (Simply Wall St.) +5.44%
May-12-21 04:05PM	Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results (PR Newswire) -8.47%
02:45PM	Marker Therapeutics, Inc. to Host Earnings Call (ACCESSWIRE)
Apr-29-21 04:05PM	Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021 (PR Newswire)
Apr-27-21 07:41PM	Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting (PR Newswire)
Apr-08-21 03:23PM	Study shows wearables could detect COVID-19 earlier (Yahoo Finance Video) +6.31%
Apr-07-21 08:32AM	Do Options Traders Know Something About Marker Therapeutics (MRKR) Stock We Don't? (Zacks) -8.85%
Mar-16-21 04:57PM	Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock (PR Newswire)
Mar-15-21 07:00AM	Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference (PR Newswire)
Mar-12-21 08:00AM	Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock (PR Newswire) -23.32%
Mar-11-21 04:10PM	Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock (PR Newswire)
Mar-09-21 04:12PM	Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results (PR Newswire) +6.81%
Mar-03-21 07:00AM	Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant (PR Newswire)
Mar-01-21 05:03AM	What Type Of Shareholders Make Up Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Share Registry? (Simply Wall St.) +5.79%
Jan-13-21 07:00AM	Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates (PR Newswire) +8.33%
Jan-05-21 07:00AM	Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial (PR Newswire) +17.69%
Nov-30-20 02:30AM	Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-09-20 04:01PM	Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results (PR Newswire)
03:15PM	Marker Therapeutics, Inc. to Host Earnings Call (ACCESSWIRE)
Nov-02-20 07:00AM	Marker Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, November 9, 2020 (PR Newswire)
Sep-17-20 07:00AM	Marker Therapeutics to Present at the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (PR Newswire)
Aug-10-20 04:00PM	Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results (PR Newswire)
Jun-30-20 07:00AM	Marker Therapeutics Announces New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates (PR Newswire)
Jun-23-20 07:00AM	Marker Therapeutics Receives USAN Approval for "zelenoleucel" as Nonproprietary Name for MT-401, Multi-Tumor-Associated Antigen Targeted T Cell Product for Acute Myeloid Leukemia (PR Newswire)
Jun-10-20 02:14PM	Hedge Funds Never Been Less Bullish On Marker Therapeutics, Inc. (MRKR) (Insider Monkey)
Jun-02-20 06:34AM	We're Not Very Worried About Marker Therapeutics's (NASDAQ:MRKR) Cash Burn Rate (Simply Wall St.)
May-29-20 08:00AM	Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting (PR Newswire) -8.10%
May-13-20 05:01PM	Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at ASCO 2020 Annual Meeting (PR Newswire)
May-11-20 04:05PM	Marker Therapeutics Reports First Quarter 2020 Operating and Financial Results (PR Newswire)
May-04-20 04:05PM	Marker Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, May 11, 2020 (PR Newswire)
Apr-30-20 12:32PM	Penny Stocks to Buy Using Technical Analysis for May 2020 (Investopedia) +21.37%
Apr-29-20 04:05PM	Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia (PR Newswire) +14.65%
Apr-11-20 01:59PM	Coronavirus update: 1.72 million cases worldwide, 106,469 deaths; U.S. surpasses Italy in number of fatalities (MarketWatch)
Apr-10-20 06:24PM	FDA grants emergency authorization to two blood purification systems (MarketWatch)
Mar-12-20 04:01PM	Marker Therapeutics Reports Full Year 2019 Operating and Financial Results (PR Newswire) -19.70%
Mar-02-20 07:00AM	Marker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million (PR Newswire) +10.12%
Feb-18-20 07:00AM	Marker Therapeutics to Present at Two Upcoming Investor Conferences (PR Newswire)
Feb-11-20 07:00AM	Marker Therapeutics Announces Update to its Clinical Program in AML (PR Newswire) +5.95%
Jan-06-20 10:01AM	Such Is Life: How Marker Therapeutics (NASDAQ:MRKR) Shareholders Saw Their Shares Drop 58% (Simply Wall St.) +6.27%

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRKR

Marker Therapeutics Inc

Upgrade your FINVIZ experience